Home - Cingulate Inc
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity …
Dr. Alice Mao, MD - Advisors | Cingulate Inc
The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.
SEC Filings - Cingulate Inc
Dec 15, 2025 · Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx …
Final Study Completed for Cingulate’s Lead Asset CTx-1301
Jan 7, 2025 · The subjects in the study were given a single 50mg dose of CTx-1301, Cingulate’s highest dosage, to determine if the medication can be taken in fed and fasted states. No …
Board of Directors - Cingulate Inc
Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with …
Press Releases - Cingulate Inc
Nov 7, 2024 · KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed …
Contact Us - Cingulate Inc
Drop us an email or phone call. We'd love to hear from you! Contact Us Cingulate Inc 1901 W 47th Place Kansas City, KS 66205 [MAP] (913) 942-2300 [email protected] Investor …
Cingulate to Participate in Benzinga All Live Access Event
The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.
0001493152-24-004061 | 8-K | iXBRL Viewer | Cingulate INC
Cingulate INC SEC filing: Form 8-K on 01/29/2024 (0001493152-24-004061).
Jay Roberts - Board Member | Cingulate Inc
The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.